Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Cash & Equivalents (2016 - 2025)

Avanos Medical's Cash & Equivalents history spans 12 years, with the latest figure at $89.0 million for Q3 2024.

  • For Q3 2024, Cash & Equivalents fell 16.9% year-over-year to $89.0 million; the TTM value through Sep 2024 reached $89.0 million, down 16.9%, while the annual FY2023 figure was $87.7 million, 31.32% down from the prior year.
  • Cash & Equivalents for Q3 2024 was $89.0 million at Avanos Medical, down from $92.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $187.7 million in Q1 2020 and bottomed at $75.8 million in Q1 2024.
  • The 5-year median for Cash & Equivalents is $104.3 million (2022), against an average of $114.0 million.
  • The largest annual shift saw Cash & Equivalents tumbled 46.67% in 2021 before it rose 19.63% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $111.5 million in 2020, then rose by 6.28% to $118.5 million in 2021, then grew by 7.76% to $127.7 million in 2022, then crashed by 31.32% to $87.7 million in 2023, then grew by 1.48% to $89.0 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Cash & Equivalents are $89.0 million (Q3 2024), $92.2 million (Q2 2024), and $75.8 million (Q1 2024).